Business
Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology
Illumina, Inc. (NASDAQ: ILMN) today announced that reimbursement has been granted for its FDA-approved in vitro diagnostic (IVD) TruSight™ Oncology (TSO) Comprehensive test. The reimbursement decision from the Centers for Medicare and Medicaid Services (CMS) will expand access to comprehensive genomic profiling (CGP) and the growing role of personalized genomics in oncology care.
About this update from Illumina, Inc.
[{"type":"text","content":"The FDA-approved comprehensive genomic profiling test will be reimbursed at a rate of $2,989.55 per test, helping to advance adoption in the US healthcare system","length":161,"tagName":"p"},{"type":"text","content":"SAN DIEGO, Jan. 20, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that reimbursement has been granted for its FDA-approved in vitro diagnostic (IVD) TruSight™ Oncology (TSO) Comprehensive test. The reimbursement decision from the Centers for Medicare and Medicaid Services (CMS) will expand access to comprehensive genomic profiling (CGP) and the growing role of personalized genomics in oncology care.","length":423,"tagName":"p"},{"type":"image","alt":"Illumina TruSight™ Oncology Comprehensive is now reimbursed through the Centers for Medicare and Medicaid Services; enabling broader access to precision oncology solutions for patients with advanced cancer.","displaySize":"","headline":null,"caption":"Illumina TruSight™ Oncology Comprehensive is now reimbursed through the Centers for Medicare and Medicaid Services; enabling broader access to precision oncology solutions for patients with advanced cancer.","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":226,"url":"https://media.zenfs.com/en/prnewswire.com/71cf70e8cfa7aa1908472d1af952a49d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/z0oHajl.6I_5Wv18kMBddA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5ODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/71cf70e8cfa7aa1908472d1af952a49d","width":400,"height":226}},"href":"https://mma.prnewswire.com/media/2864945/Illumina_TruSight.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""This decision helps removes barriers that have limited adoption of comprehensive genomic profiling for patients, empowering more healthcare providers to deliver precision oncology insights that will improve outcomes," said John Fox, MD, senior director, Market Access and Government Affairs at Illumina.","length":319,"tagName":"p"},{"type":"text","content":"TSO Comprehensive gives clinicians the ability to simultaneously assess hundreds of genes—including relevant cancer biomarkers—to inform treatment decisions. With reimbursement now in place, more laboratories will be able to bring CGP in-house and deliver clinically actionable results to their ...